{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:40:56Z","timestamp":1792183256096,"version":"4.4.0"},"reference-count":69,"publisher":"SAGE Publications","issue":"13-14","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Human Gene Therapy"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:p>\n                    Adeno-associated virus (AAV) vectors represent a novel tool for the delivery of genetic therapeutics and enable the treatment of a wide range of diseases. Success of this new modality is challenged, however, by cases of immune-related toxicities that complicate the clinical management of patients and potentially limit the therapeutic efficacy of AAV gene therapy. While significant progress has been made to manage immune-related liver enzyme elevations following systemic AAV delivery in humans, recent clinical trials utilizing high vector doses have highlighted a new challenge to AAV gene transfer\u2014activation of the complement system. While current\n                    <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                    models implicate AAV-specific antibodies in the initiation of the classical complement pathway, evidence from\n                    <jats:italic toggle=\"yes\">in vivo<\/jats:italic>\n                    pre-clinical and clinical studies suggests that the alternative pathway also contributes to complement activation. A convergence of AAV-specific, environmental, and patient-specific factors shaping complement responses likely contributes to differential outcomes seen in clinical trials, from priming of the adaptive immune system to serious adverse events such as hepatotoxicity and thrombotic microangiopathy. Research focused on the interplay of patient-specific and AAV-related factors driving complement activation is needed to understand and identify critical components in the complement cascade to target and devise strategies to mitigate vector-related immune responses.\n                  <\/jats:p>","DOI":"10.1089\/hum.2023.194","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T07:19:00Z","timestamp":1705907940000},"page":"425-438","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":39,"title":["Complement System Response to Adeno-Associated Virus Vector Gene Therapy"],"prefix":"10.1177","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2278-052X","authenticated-orcid":false,"given":"Elizabeth","family":"Kropf","sequence":"first","affiliation":[{"name":"Immunology Department, Spark Therapeutics, Inc., Philadelphia, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Markusic","sequence":"additional","affiliation":[{"name":"Immunology Department, Spark Therapeutics, Inc., Philadelphia, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Majowicz","sequence":"additional","affiliation":[{"name":"Immunology Department, Spark Therapeutics, Inc., Philadelphia, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Mingozzi","sequence":"additional","affiliation":[{"name":"Immunology Department, Spark Therapeutics, Inc., Philadelphia, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaudia","family":"Kuranda","sequence":"additional","affiliation":[{"name":"Immunology Department, Spark Therapeutics, Inc., Philadelphia, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.12.007"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.01.001"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00262"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-021-00892-7"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017860"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202250042"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12500"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/595830"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/imcb.12324"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01990-07"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.999021"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.06.002"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2023.018"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1007102"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2017.05.014"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.660757"},{"key":"e_1_3_5_18_2","first-page":"109","article-title":"The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation","volume":"21","author":"Lachmann PJ","year":"1975","unstructured":"Lachmann PJ, , Halbwachs L. The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clinical Exp Immunol, 1975; 21:109\u2013114.","journal-title":"Clinical Exp Immunol"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-017-0661-x"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.154.3.856"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2019.07.032"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2004.02627.x"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2018.015"},{"key":"e_1_3_5_24_2","unstructured":"Wilson JM. Adeno-Associated Virus-Related Toxicities in Nonhuman Primates. U.S. Food & Drug Administration: Cellular Tissue and Gene Therapies Advisory Committee. 2021. Available from: https:\/\/www.fda.gov\/media\/151950\/download [Last accessed: November1 2023]."},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.04.019"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.04.017"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.04.017"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.04.017"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00082-09"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-017-0646-9"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwad074"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-021-00249-8"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-558296"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2020.02.006"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.117.5_Part_1.1440"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2016.12.017"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00257"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2009.139"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2013.08.001"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2012.06.001"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.10.009"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.811504"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1208981"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012037"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.860689"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.950651"},{"key":"e_1_3_5_47_2","unstructured":"Solid. Solid Biosciences Announces FDA Lifts Clinical Hold on IGNITE DMD Clinical Trial. 2020. Available from: https:\/\/www.solidbio.com\/about\/media\/press-releases\/solid-biosciences-announces-fda-lifts-clinical-hold-on-ignite-dmd-clinical-trial [Last accessed: February19 2024]."},{"key":"e_1_3_5_48_2","unstructured":"Johnson V. PF-06939926 Continues to Show Safety and Efficacy in Duchenne Muscular Dystrophy. NeurologyLive; 2021. Available from: https:\/\/www.neurologylive.com\/view\/pf-06939926-safe-efficacious-dmd [Last accessed: November1 2023]."},{"key":"e_1_3_5_49_2","unstructured":"Pfizer. Pfizer's New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study. 2020. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizers-new-phase-1b-results-gene-therapy-ambulatory-boys [Last accessed: November1 2023]."},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa7322"},{"key":"e_1_3_5_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2020.11.054"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006419"},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200676"},{"key":"e_1_3_5_54_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51519"},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.94.15_supplement.5483"},{"key":"e_1_3_5_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.001"},{"key":"e_1_3_5_57_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-023-00585-7"},{"key":"e_1_3_5_58_2","unstructured":"4DMT. Update from INGLAXA Phase 1\/2 Clinical Trials & Development Plans for 4D-310 Genetic Medicine for Fabry Disease Cardiomyopathy. WORLDSymposium 2023. 2023. Available from: https:\/\/ir.4dmoleculartherapeutics.com\/static-files\/f867a7b1-c72d-4038-8c5d-67676b7afc05 [Last accessed: November1 2023]."},{"key":"e_1_3_5_59_2","unstructured":"4DMT. 4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1\/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposium\u2122. 2023. Available from: https:\/\/ir.4dmoleculartherapeutics.com\/news-releases\/news-release-details\/4d-molecular-therapeutics-presents-interim-data-4d-310-inglaxa [Last accessed: November1 2023]."},{"key":"e_1_3_5_60_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11041067"},{"issue":"4","key":"e_1_3_5_61_2","first-page":"12","article-title":"Extended results from first-in-human clinical trial of RP-A501 (AAV9:LAMP2B) gene therapy treatment for Danon disease","volume":"30","author":"Greenberg B","year":"2022","unstructured":"Greenberg B, , Rossano J, , Epstein S, et al. Extended results from first-in-human clinical trial of RP-A501 (AAV9:LAMP2B) gene therapy treatment for Danon disease. Mol Ther, 2022; 30(4):12\u201313.","journal-title":"Mol Ther"},{"key":"e_1_3_5_62_2","unstructured":"Rocket. Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial of RP-A501 in Danon Disease. Available from: https:\/\/ir.rocketpharma.com\/news-releases\/news-release-details\/rocket-pharmaceuticals-announces-positive-updates-phase-1 [Last accessed: November1 2023]."},{"key":"e_1_3_5_63_2","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.114.001105"},{"key":"e_1_3_5_64_2","unstructured":"LogicBio. LogicBio Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update. 2022. Available from: https:\/\/www.prnewswire.com\/news-releases\/logicbio-therapeutics-reports-second-quarter-2022-financial-results-and-provides-corporate-update-301605458.html [Last accessed: November1 2023]."},{"key":"e_1_3_5_65_2","doi-asserted-by":"publisher","DOI":"10.1039\/c5mb00736d"},{"key":"e_1_3_5_66_2","doi-asserted-by":"publisher","DOI":"10.1309\/ajcpxpd7zqxntial"},{"key":"e_1_3_5_67_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI173510"},{"key":"e_1_3_5_68_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02438-9"},{"key":"e_1_3_5_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2018.06.005"},{"key":"e_1_3_5_70_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci122372"}],"container-title":["Human Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/hum.2023.194","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2023.194","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2023.194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:57:03Z","timestamp":1777449423000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/hum.2023.194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":69,"journal-issue":{"issue":"13-14","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1089\/hum.2023.194"],"URL":"https:\/\/doi.org\/10.1089\/hum.2023.194","relation":{},"ISSN":["1043-0342","1557-7422"],"issn-type":[{"value":"1043-0342","type":"print"},{"value":"1557-7422","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}